Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-Vac-Mn + toripalimab
- Development stage
- Phase 1
- Lead developer
- Xiangya Hospital, Central South University
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous, Subcutaneous, Topical
01
Overview
Neo-Vac-Mn + toripalimab is an investigational combination immunotherapy regimen being developed by Xiangya Hospital of Central South University for the treatment of metastatic cutaneous melanoma. The therapy consists of Neo-Vac-Mn, a personalized cancer vaccine composed of patient-specific neoantigen peptides identified through tumor sequencing, and toripalimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. The vaccine is designed to prime the immune system to recognize and attack tumor cells expressing specific mutations, while toripalimab acts as a checkpoint inhibitor to prevent the tumor from evading the immune response by blocking the PD-1/PD-L1 pathway. The regimen also incorporates adjuvants such as recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and topical imiquimod, a Toll-like receptor 7 (TLR7) agonist, to enhance the dendritic cell-mediated presentation of the neoantigens and boost the overall anti-tumor immune response.
- Brand names
- Tuoyi
- Other names
- Personalized NeoAntigen Cancer Vaccine combined with Anti-PD-1Neo-Vac-Mn and Toripalimab in Metastatic Melanoma
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)PDCD1 (Programmed cell death protein 1 receptor)TLR7 (Toll-like receptor 7)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Neo-Vac-Mn + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-Vac-Mn + toripalimab.